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decreased NADH oxidation activity 2.5–4.8 times depending on the used electron acceptor. The apparent Km
for NADH was 5.2 and 10.4 μM for the mutant and wild type, respectively. Analysis of the inhibitory effect of
NAD+ on activity showed that the E95Q mutation caused a 2.4-fold decrease of KiNAD+ in comparison to the
wild type enzyme. ADP-ribose, which differs from NAD+ by the absence of the positively charged
nicotinamide moiety, is also a competitive inhibitor of NADH binding. The mutation caused a 7.5-fold
decrease of KiADP-ribose relative to wild type enzyme. Based on these ﬁndings we propose that the negative
charge of Glu95 accelerates turnover of Complex I by electrostatic interaction with the negatively charged
phosphate groups of the substrate nucleotide during operation, which facilitates release of the product NAD+.
The E95Q mutation was also found to cause a positive shift of the midpoint redox potential of the FMN, from
−350 mV to −310 mV, which suggests that the negative charge of Glu95 is also involved in decreasing the
midpoint potential of the primary electron acceptor of Complex I.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
The crystallographic structure of the hydrophilic domain of
Complex I from T. thermophilus shows a cavity close to the cofactor
FMN in the catalytic Nqo1 subunit where the NADH may be bound
[1,2]. The deep end of this cavity contains two invariant amino acid
residues, glutamate 97 and tyrosine 180 that are exposed to the
solvent and located in the vicinity of the ﬂavin, and have been
suggested to interact with the nicotinamide group of NADH [1]. The
double mutation Y204C/C206G in human Complex I (Y204 is the
counterpart of Y180 in T. thermophilus) causes severe symptoms [3]
that could be due to the interaction of these residues with FMN or/and
NADH [2]. However, the role of the negatively charged Glu97 has so far
not been assessed. Glu97 might cause a decrease of the midpoint
redox potential of the non-covalently bound FMN, the value of which
was found to be very low (−380 mV [4]; or −350 mV [5]) in
comparison to the value of −220 mV for free FMN in aqueous solution.
An example of such modulation of the redox properties of non-
covalently bound ﬂavin by acidic amino acid residues has been; HAR, hexaammineruthenium
ide hypoxanthine dinucleotide
phoribose sodium salt; PMSF,
rina.verkhovskaya@helsinki.ﬁ
ll rights reserved.described for ﬂavodoxin from Clostridium beijerinckii [6]. Four acidic
residues, including Glu97, surround the isoalloxazine ring of the FMN
in the T. thermophilus Complex I at a distance of 4–6 Å (PDB entry
2FUG, chain 1); each of these residues may contribute to the negative
shift of the redox potential of the cofactor. In order to assess the role of
the strictly conserved glutamate 97 we mutated the corresponding
glutamate 95 in the NuoF subunit of the E. coli Complex I to glutamine.
Here, we report the consequences of this mutation, which we ascribe
to loss of negative charge in the active site.
2. Materials and methods
2.1. 3-D structure prediction of NuoF subunit of E. coli Complex I
Modeling of the NuoF subunit of Complex I from E. coli was
performed by submitting a model request to a Swiss-Model server [7]
(http://swissmodel.expasy.org) using an Alignment Mode. Multiple
sequence alignment of 35 homologues of the NuoF subunit from
bacterial and eukaryotic genomes sharing not less than 40% of identity
was done using ClustalX software (1.81). For homology modeling the
sequence of the Nqo1 subunit of T. thermophilis Complex I with the
known crystal structure (PDB entry 2FUG, chain 1) was chosen as a
template. The obtained 3-D model of the NuoF subunit was reﬁned by
superposition with the atomic coordinates of the crystal structure of
the Nqo1 subunit of T. thermophilis Complex I using DeepView/Swiss-
PdbViewer software (3.7) [8].
Table 2
Oligonucleotides used in this study
Oligonucleotide Sequencea
UpFF GATCGACTTCGACGTGCGTAAG
LowFR ACCGAAGTAGACGTTGTCGTGC
FE95Q CCGATGAAATGCAGCCGGGCACC
a Mutated nucleotide is in italic bold.
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The used bacterial strains were based on the E. coli strain GR70N
[9] and the used plasmids are listed in Table 1. Genetic manipulations
were carried out using TOP10 (Invitrogen), JM109 and BMH 71-18
mutS (Promega) E. coli strains. The oligonucleotides used are listed
in Table 2.
The NuoF-deﬁcient strain GRF5 was constructed by deleting the
internal part of the nuoF gene from the chromosomal DNA of the
GR70N E. coli strain, and replacing it by the unidirectionally
transcribing kanamycin resistance cassette.
For this purpose, the nuoF gene with up- and downstream regions
was ampliﬁed from genomic DNA of the E. coli GR70N strain with
sense UpFF and antisense LowFR oligonucleotides, and the ca. 3 kbp
product was ligated in the pGEM-T Easy vector (Promega) resulting in
pGEM-LFR. The HincII-fragment of pUC4K containing the KmR cassette
was inserted in the EcoRV and BspEI sites of pGEM-LFR after ﬁlling the
sticky ends with deoxynucleotide thriphosphates and T4 DNA
polymerase yielding pGEM-ﬂF::Km. The NotI-fragment from pGEM-
ﬂF::Km containing the kanamycin resistance cassette with ﬂanks
complementary to the corresponding regions on chromosomal DNA
was ligated into NotI-linearized pKO3. The resulting pKO-ﬂF::Km
plasmidwas used for the transformation of GR70N competent cells and
gene replacement experiments basedonhomologous recombination as
described by Link et al. [10]. The selected kanamycin resistant GRF5
strain had the 998 bp-deletion of the chromosomal nuoF gene from
143d to the 1140th oligonucleotide.
The pGEM-LFR vector described above was used as DNA template
for mutagenesis. The E95Q point mutation was introduced into
pGEM-LFR using the GeneEditor in vitro site-directed mutagenesis
system (Promega) according to the manufacturer's instructions,
followed by DNA sequencing of the mutated gene. The PspOMI–
SalI-fragment of the pGEM-LFR plasmid bearing the point mutation
was ligated into NotI–SalI-digested pKO3. The resulting plasmid was
used for restoration of the mutated nuoF gene on the chromosome of
the nuoF-deﬁcient GRF5 strain as described by Link et al. [10] with
selection of kanamycin-sensitive clones. Correct introduction of the
mutation in the chromosome was veriﬁed by DNA sequencing.
2.3. Bacterial growth and membrane preparation
Bacteria were routinely grown in LB medium at 37 °C with
appropriate antibiotics at indicated concentrations (μg/ml); ampicillin
(100); streptomycin (50); kanamycin (50); chloramphenicol (20).
Growth tests were carried out under aerobic conditions at 37 °C in rich
(LB) and minimal, M9, medium, containing DL-malate as the sole
carbon source.
For membrane preparation with further puriﬁcation of Complex I,
the E. coli strain GR70N or GRF-E95Q was grown aerobically in a 25 L
fermentor in LB medium at 37 °C. The cells were harvested in the late
exponential growth phase. Membrane preparation was done as
described in [11] with one exception: before passing through an APV
Gaulin homogenizer, the cells were suspended in buffer containingTable 1
Bacterial strains and plasmids
Strain or plasmid Genotype/relevant properties Ref
Strains
GR70N F− thi rpsL gal, SmR, wild type Complex I [9]
GRF5 GR70N, nuoF::KmR This study
GRF-E95Q GR70N, nuoF E95Q This study
Plasmids
pGEM-T Easy ApR, PCR product cloning vector Promega
pUC4K ApR, KmR, source of kanamycin resistance cassette Amersham
pKO3 sacB, pSC101, CmR, gene replacement vector [10]50 mM HEPES/KOH, pH 7.0, 100 mM KCl, 2 mM MgCl2, 0.5 mM PMSF
using UltraTurrax.
2.4. Puriﬁcation of Complex I
The puriﬁcation was based on the protocol described in [11] with
the followingmodiﬁcations. For a single puriﬁcation, membranes with
a total of 650–700 mg of protein were used. Membranes were
solubilized with DDM (Anatrace) and the extract (140–150 ml) was
loaded at a 18 cm/h ﬂow rate onto a 130 ml bed volume of a DEAE–
Trisacryl M (BioSepra) column equilibrated with 100 mM NaCl in
buffer A containing 50 mM Mes/NaOH, pH 6.0 and 0.05% DDM. Then
the columnwaswashedwith 400ml of equilibration buffer and eluted
with 200 ml of 180 mM NaCl in buffer A at a 30 cm/h ﬂow rate.
Concentrated fractions enriched with Complex I were adjusted to
100 mM of NaCl by dilution with buffer A, then the protein solution
was applied onto a 30ml bed volume of a DEAE–Trisacryl M column at
a 17 cm/h ﬂow rate. Then the column was washed with 40 ml of
equilibration buffer and eluted at a17 cm/h ﬂow rate with 100 ml of
140 mM NaCl in buffer A.
2.5. Measurements of catalytic activity
HAR and DQ reductase activities of puriﬁed or membrane-bound
Complex I were measured as described in [11] in the buffer
containing 25 mM HEPES–BTP, pH 7.5 and 3.5 mM KCl. FeCy
reductase activity was measured in the same buffer in the presence
of 50 μM NADH, 1 mM FeCy, and reduction of FeCy was followed at
420 nm (ɛ=1 mM−1 cm−1). For the determination of the inhibitory
effect of NAD+ and ADP-ribose on NADH/HAR oxidoreductase activity
of mutated and wild type Complex I, a ﬁxed amount of these
chemicals was added into the reaction mixture before the start of the
reaction with the protein. Each titration curve presented in this study
is the mean of at least three independent measurements.
2.6. Other analytical procedures
Protein concentrations were determined by the BCA protein assay
reagent kit (Pierce) with bovine serum albumin as a standard. 10–20%
gradient polyacrylamide gels were used for the analysis of purity of
wild type and mutated Complex I.
2.7. Optical redox titration
Spectroelectrochemical redox titrations of puriﬁed mutated and
wild type Complex I were done at pH 7.5 according to the procedure
described in [5]. The obtained data were analyzed using MATLAB (The
Mathworks, South Natick, MA).
3. Results
3.1. Location of the invariant glutamate 95 in the NADH-binding site of
E. coli Complex I
Prediction of the 3-D structure of the NuoF subunit from the E. coli
Complex I is based on homology modeling using the resolved
structure of the T. thermophilis Nqo1 subunit as a template (PDB
Fig. 1. (A) Location of the invariant E95 and Y178 with respect to the FMN in the NADH-binding site in the modeled NuoF subunit of Complex I from E. coli. (B) Conserved negatively
charged amino acid residues surrounding the FMN. Atomic distances are represented in Å. Structures are drawn using the VMD program [12].
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of E97 from Nqo1 in T. thermophilus Complex I, and also faces the
hydrophilic NADH-binding cavity at a distance of 4.8 Å from the N(3)
of the FMN isoalloxazine ring (Fig. 1A). Another three strictly
conserved acidic residues (D92, E93 and D101) that surround the
ﬂavin have their carboxyl groups located at a distance of 4–6 Å from
the isoalloxazine ring of this cofactor (Fig. 1B).
3.2. Activity of membrane bound and puriﬁed E95Q mutant of Complex I
Bacterial strains used in this study have two membrane-bound
NADH:quinone oxidoreductases: NDH-I (Complex I) and NDH-II
(NADH dehydrogenase II), which both oxidize NADH [13]. In order
to measure the rate of NADH oxidation by mutated and wild type
Complex I in membranes, and to avoid the interference with NDH-II,
the analog of NADH, namely dNADH, was used as an electron donor
since it is speciﬁc only for Complex I. The dNADH:HAR oxidoreductase
activity was decreased approximately ﬁve times in the E95Qmutant in
comparison to wild type, while the rate of dNADH:DQ oxidoreduction
declined only 2.5 times. After puriﬁcation of the wild type and
mutated enzymes, their HAR and DQ reductase activities were
measured using NADH, and the correlation between the rates of the
reactions remained nearly the same as in membranes (Table 3). The
rate of NADH oxidation in the puriﬁed enzymes was also measured
using FeCy, another artiﬁcial electron acceptor of Complex I. The
NADH:FeCy oxidoreductase activity of the E95Q mutant was
decreased 2.5 times relative to wild type, as was the case for the DQ
reductase activity.
Analysis by SDS-PAGE (Fig. 2) showed that the decreased rates in
the puriﬁed E95Q mutant could not be explained by contamina-
tions. The purity of the mutant enzyme was the same as of the wild
type.Table 3
Activities of wild type and mutated Complex I in membrane-bound and puriﬁed states
Preparation Activity, μmol of (d)NADH×min−1×mg−1
WT E95Q
Membranes
dNADH:HAR reductase 1.9±0.1 0.4±0.1
dNADH:DQ reductase 0.8±0.1 0.3±0.1
Puriﬁed Complex I
NADH:HAR reductase 118.8±7.9 24.4±1.5
NADH:DQ reductase 28.7±2.6 11.5±1.5
NADH:FeCy 127.7±4.5 51.7±2.73.3. Kinetic properties of wild type and mutated Complex I
Determination of Vmax and the apparent Michaelis constants of
NADH:HAR oxidoreduction for wild type and mutated Complex I
showed that both of these kinetic parameters changed signiﬁcantly
due to the E95Q mutation, which indicates a possible alteration of
substrate afﬁnity or/and a disturbance in the catalytic site. The values
of Vmax (138 and 26.5 μmol NADH×min−1×mg−1), KmHAR (67 and
15 μM) and KmNADH (10.4 and 5.2 μM) were all decreased signiﬁcantly in
the E95Q mutant, as compared with wild type (Fig. 3). It should be
noted that we have determined Km for HAR for the wild type E. coli
Complex I as 67 μM, which is much lower than the value of 0.5 mM
published in [14] for the bovine enzyme. This difference could be
explained by structural differences between the bacterial and
mitochondrial enzymes. Since the basic kinetic parameters are only
of limited value in a reaction as complicated as that of Complex I,
where the mechanism is not known [15], we tested the nucleotide
binding site in a more direct way.
Determination of the dissociation constant for NAD+ can give a clue
to the role of glutamate 95 in the NADH-binding site. Competitive
inhibition of NADH:HAR reductase activity by NAD+ in puriﬁed wild
type Complex I and in the E95Q mutant in the presence of different
NADH concentrations is presented as Dixon plots in Fig. 4.Fig. 2. Coomassie Blue-stained 10–20% SDS-PAGE gel of puriﬁed wild type Complex I
(lane 2, 30 μg) and E95Q mutant (lane 3, 25 μg). Lane 1: molecular mass markers (kDa).
The assignment of the observed bands to individual subunits of Complex I is given on
the right.
Fig. 3. Double-reciprocal plots for the NADH:HAR reductase reaction catalyzed by
puriﬁed wild type (circles) and E95Q mutant (squares) Complex I in the presence of
500 μM HAR (A) and 200 μM NADH (B). The activity is expressed as mmol of NADH
oxidized by milligram of protein per minute.
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Complex I from E. coli was found to be 0.93 mM, and for the mutant
this constant decreased approximately 2.4-times to 0.39 mM. This
suggests that NAD+ binds more tightly in the E95Q mutant,
dissociating less quickly from the site, thus preventing entrance of a
new molecule of NADH.Fig. 4. Competitive inhibition of NADH:HAR reductase activity by NAD+ in puriﬁed: (A)
wild type (circles) and (B) E95Q mutant (squares) Complex I. Results are presented as
Dixon plots; all titrations were done at 350 μM HAR, concentrations of NADH (μM) are
indicated above the lines. The activity is expressed as mmol of NADH oxidized by
milligram of protein per minute.Since KiNAD+ was determined using NADH:HAR oxidoreductase
activity the decreased value of this parameter in the mutant might
also be due to an effect of the mutation on HAR binding. To test this
possibility we checked the inhibitory effect of NAD+ on the NADH:DQ
oxidoreductase activity of wild type and mutated Complex I in
membranes (data not shown). The results of this experiment still
clearly showed a similar difference between KiNAD+ for the mutant
(0.3 mM) andwild type (1mM) enzymes, indicating that themutation
affects the NAD-binding site rather than the site where the electron
acceptor is bound.
Despite the fact that NAD+ has a positive charge on the nitrogen
atom of the pyridine ring, the total charge of the oxidized nucleotide at
neutral pH is negative because of the presence of two phosphate
groups. Therefore, the anionic glutamate in the NADH-binding site
could be involved in the process of product dissociation by electrostatic
repulsion. If this is the case, a change of this amino acid residue to a
neutral one should also affect the binding of other negatively charged
competitive inhibitors of NADH oxidation, e.g. ADP-ribose [16]. The
structure of this compound is similar to NAD+ but it lacks the positively
charged nicotinamide group. To check this suggestionwe compared the
inhibitory effects of ADP-ribose onNADH:HAR oxidoreductase reaction
in puriﬁed wild type Complex I and in the E95Q mutant (Fig. 5).
In the wild type enzyme the determined KiADP-ribose (0.97 mM) was
comparable to that of KiNAD+. In contrast, in the mutant the inhibitory
effect of ADP-ribosewas 7.5 times stronger (KiADP-ribose=0.13 mM). This
ﬁnding further supports the notion that the negative charge of Glu95
has the effect of expelling the product NAD+ from the substrate-
binding site.
3.4. Spectroelectrochemical redox titration of the E95Q mutant
Glutamate 95 is one of four conserved negatively charged amino
acid residues in the vicinity of FMN (Fig. 1B), which might be involved
in maintaining the low redox potential of this cofactor. Consequently,
removing one of these negative charges is expected to shift theFig. 5. Competitive inhibition of NADH:HAR reductase activity by ADP-ribose in puriﬁed
Complex I from wild type (A) and E95Q mutant (B). Results are presented as Dixon
plots; all titrations were done at 350 μM of HAR, concentrations of NADH (μM) are
indicated above the lines. The activity is expressed as mmol of NADH oxidized by
milligram of protein per minute.
Fig. 6. Optical redox titration of the puriﬁed mutated Complex I. (A) Difference spectra (reduced minus oxidized) of the mutant obtained at redox potentials from −500 to −40 mV
with step of 20 mV. (B) Titration curves at 450 nm for the wild type (circles) and for the mutant (squares). (C) The ﬁrst derivatives of the titration curves at 450 nm for the wild type
and for the mutant (obtained by subtraction of spectra with adjacent potentials). Inset: the difference spectrum “−320 mV minus −280 mV”.
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redox titrations of the puriﬁed wild type and E95Q mutant enzymes
were carried out using optical spectroscopy. Changes in the spectral
regionwhere FMN absorbs maximally are presented in Fig. 6A (optical
spectra for wild type Complex I are not shown). Since the oxidized
ﬂavin has a very well-deﬁned absorbance maximum at 450 nm, we
compared titration curves of the mutant enzymewith the wild type at
this wavelength (Fig. 6B). One has to keep in mind that although the
iron–sulfur clusters of Complex I are also absorbing in this region, it is
nevertheless possible to extract the midpoint redox potential of the
two-electron carrier FMN from such data [5]. Comparison of the
titration curves of the mutant and wild type enzyme clearly shows
that they are nearly the same, except for a component characterized
by the maximal slope (Fig. 6B). This component corresponds to the
potential rangewheremostly the FMN spectrum is changing (see inset
Fig. 6C). The part of the titration curve with maximal slope was shifted
in the mutant relative to the wild type to a more positive redox
potential. In order to accurately determine the Em of the ﬂavin in the
E95Q mutant, we plotted the ﬁrst derivatives of the redox titration
curves at 450 nm (Fig. 6C). As seen from this ﬁgure, the substitution of
glutamate 95 by glutamine caused a positive shift in the midpoint
potential of the ﬂavin of 40 mV and resulted in the value of −310 mV
(versus −350 mV in wild type [5]). The difference spectrum, −320 mV
minus −280 mV (Fig. 6C, inset) from the redox titration of the mutant
clearly conﬁrms that the major contribution to the absorbance change
in this potential interval indeed derives from a reduced minus
oxidized difference spectrum of FMN.
4. Discussion
The analysis of the kinetic parameters of NADH oxidation by wild
type and mutated E95Q Complex I indicated that the mutation affects
the afﬁnities to both substrate (NADH) and product (NAD+) of the
reaction and decreases the turnover of the enzyme. A drop by a factor
of 2.5 in the rate of NADH oxidation by the mutant Complex I was
observed if FeCy or ubiquinonewere used as an electron acceptors, but
in the case of HAR the Vmax appeared to be 5 times less than in the
wild type. This suggests that in the ﬁrst two cases the glutamate
replacement altered either nucleotide binding/debinding or/and the
efﬁciency of the electron transfer from NADH to FMN, while in the
latter case themutationmay additionally cause a change in the afﬁnity
for HAR which would be in line with an idea suggested by Zickermann
et al. [17].
Since Glu95 has its side chain oriented towards the NADH-binding
cavity located in front of the FMN at a distance of 4.8 Å fromN(3) of its
isoalloxazine ring (Fig. 1A), the suggestion that E95 interacts with the
nicotinamide moiety of NADH [1] looks solid. Therefore, replacement
of the acidic Glu by the neutral Gln is a priori expected to lead to adecrease in the afﬁnity for NAD+, because of loss of electrostatic
attraction between the negatively charged carboxyl group of Glu95
and the positively charged nitrogen of the pyridine ring. However, the
opposite effect was observed. Here, one should take into account that
the overall charge of the NAD+ molecule is negative because of the two
phosphate groups, making electrostatic repulsion between the Glu95
anion and the nucleotide a deﬁnite possibility. We therefore suggest
that the main role of E95 is not in the binding of NADH, but rather in
promoting the dissociation of the product NAD+ due to electrostatic
repulsion. This is in line with the ﬁnding that the afﬁnity of the
mutated Complex I for ADP-ribose, which lacks the positive
nicotinamide moiety, was increased even further than that in case of
NAD+.
Based on the resolved crystal structure of the hydrophilic
domain of T. termophilus Complex I it was suggested that the
residues 66–69 from the glycine-rich loop of Nqo1 are involved in
binding of the nucleotide phosphate groups [1]. Our proposal does
not contradict this conclusion since the distances from Glu97 to
Gly66 and Gly67 (5.5 Å and 7.4 Å, respectively), are short enough for
electrostatic interactions between glutamate 97 and the phosphate
groups if the residues from the glycine-rich loop indeed participate
in coordination of the latter. Almost the same distances between
E95 and the corresponding glycines 63 and 64 (5.4 Å and 7.4 Å,
respectively) can be predicted from the modeled structure of the
NuoF subunit from E. coli.
The hydride transfer from NADH to FMN, the planar condensed
rings systems of which are likely positioned in parallel and close to
each other in the cavity [1], is expected to be very fast. Likewise,
further electron transfer via the iron–sulfur centers is also fast [18].
Hence, the overall rate of the reaction should be determined either by
the rate of substrate binding (NADH or HARox) or product release
(NAD+ or HARred). Since the rate of NADH oxidation also decreased by
the mutation when ferricyanide or ubiquinone were used as electron
acceptors, the effect of the mutation is likely to be determined by a
change in the afﬁnity to nucleotides. We have previously reported that
the rate of NADH binding is very fast, whereas dissociation of the
product NAD+ is much slower and likely to be rate-limiting [18]. Our
current data is in accordance with this proposal. A higher afﬁnity for
NAD+ should decrease the activity of the enzyme, as observedwith the
E95Q mutant. Therefore, the negative charge of the glutamate in the
substrate-binding site located close enough to the phosphates of the
nucleotide might have the purpose of ﬁne-tuning the site to
effectively expel product.
Another evident role of the negatively charged glutamate in the
vicinity of FMN is to decrease the redox potential of the latter. Since
free ﬂavin has an Em of −220 mV and the Em of the NADH/NAD+ pair is
−320 mV, the downshift of the midpoint potential of the protein-
bound FMN is probably important for an enzyme such as Complex I
73L. Euro et al. / Biochimica et Biophysica Acta 1787 (2009) 68–73that functions under conditions close to equilibrium. The Em value of
FMN in Complex I is −350 mV [5]. Our current results demonstrate
that Glu95, as one of the four negatively charged amino acid residues
surrounding the ﬂavin, has a share of 40 mV of the overall 130 mV
depression of the midpoint potential of the primary electron acceptor
in Complex I.
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